Oesophagogastric junction adenocarcinoma: which therapeutic approach?
about
Neoadjuvant therapy for gastroesophageal adenocarcinomaRecent developments in esophageal adenocarcinomaLocally advanced gastroesophageal junction tumor: a treatment dilemmaMicroRNA signature characterizes primary tumors that metastasize in an esophageal adenocarcinoma rat modelHigh-Grade Toxicity to Neoadjuvant Treatment for Upper Gastrointestinal Carcinomas: What is the Impact on Perioperative and Oncologic Outcomes?Current management of esophageal cancerPerioperative chemotherapy in gastroesophageal cancer. A retrospective monocenter evaluation of 42 cases.CD147 and MMP-9 expressions in type II/III adenocarcinoma of esophagogastric junction and their clinicopathological significances.[The surgical treatment of adenocarcinoma of the gastroesophageal junction: Moroccan experience through a series of 149 cases].Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial.Clinical comparison of antrum-preserving double tract reconstruction vs roux-en-Y reconstruction after gastrectomy for Siewert types II and III adenocarcinoma of the esophagogastric junction.Current treatment options for the management of esophageal cancer.The length of proximal margin does not influence the prognosis of Siewert type II/III adenocarcinoma of esophagogastric junction after transhiatal curative gastrectomy.Lymph node dissection for Siewert II esophagogastric junction adenocarcinoma: A retrospective study of 3 surgical procedures.Anti-HER agents in gastric cancer: from bench to bedside.Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care.Obesity and related risk factors in gastric cardia adenocarcinoma.Extent of lymph node removal during esophageal cancer surgery and survival.Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma.External validation of the NUn score for predicting anastomotic leakage after oesophageal resection.Surgical approaches to adenocarcinoma of the gastroesophageal junction: the Siewert II conundrum.Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.Siewert III adenocarcinoma: treatment update.Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma.Laparoscopic lymphadenectomy around the left renal vein (16a2lat) by tunneling under the pancreas for advanced Siewert type II adenocarcinoma.Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ?Palliative resection for advanced gastric and junctional adenocarcinoma: which patients will benefit from surgery?Discrepancy Between Clinical and Pathologic Nodal Status of Esophageal Cancer and Impact on Prognosis and Therapeutic Strategy.CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease.The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers.Prognostic value of resected lymph nodes numbers for Siewert II gastroesophageal junction cancer.Esophagogastric tube reconstruction with stapled pseudo-fornix in laparoscopic proximal gastrectomy: a novel technique proposed for Siewert type II tumors.Impact of Adjuvant Chemotherapy on Patients with Lymph Node-Positive Esophageal Cancer who are primarily Treated with Surgery.Prognostic significance of neuroepithelial transforming gene 1 in adenocarcinoma of the oesophagogastric junction.Adenocarcinoma of the esophagogastric junction and its background mucosal pathology: A comparative analysis according to Siewert classification in a Japanese cohortHigh-risk group of upper and middle mediastinal lymph node metastasis in patients with esophagogastric junction carcinoma
P2860
Q26746147-06DB26B2-79A7-4D2B-89DA-B22CD5989720Q26849652-F29C0668-58B9-4376-8E47-D9E8DA1A7B6FQ28082596-E0586208-0DFD-432E-AEF9-467221BD52C0Q28390889-3D52BC96-3A0F-4AA4-B8E0-8B6B5B0C45F2Q33420370-FDB3D45E-937A-47CA-B13D-21C5898A28CFQ33658207-0E73C664-7840-42ED-B77F-1EB922579CD7Q35346910-EEA566D3-CD7B-45DD-B838-DF7F0B233FABQ35406550-077A6401-4468-4898-8D7B-553FD6FF6556Q35444700-6E153DAA-A679-4119-8CBE-880BB2F7F318Q36021874-A3219C04-B338-471C-9989-CC8F18B683DBQ36050537-14144A2D-C1DF-4C29-BE4D-61F5FBBE7168Q36393867-3E36353B-EEA0-4B85-9AE1-12FFB8288BD1Q36894856-FC9ECA0A-37E6-4623-96B3-F6D138C7061FQ37656343-B196BBDD-0ED1-4DF2-9325-B3B07365DB31Q37885725-F69501C3-BB1E-47C2-B6E4-006B29589E85Q38134835-95B84901-8BF5-4CCF-933A-B6B2EAB54A6EQ38248208-16DD54C6-DB96-479E-A011-9BCD54979E69Q38415884-58D9EF76-B3FB-43CC-915E-1E5F2C32E899Q38542060-B5A5526E-CBCE-43DF-9192-12D11F99E646Q38602997-D803E7CB-6F6C-49BF-B55C-23276E6412A2Q38627318-BEDD0E40-7F6C-4A6C-8D22-F8D6DD3943D3Q38970911-8180654D-C9D9-4271-99CA-3159D606C090Q39183295-9DB9BBD6-E8BA-42F4-BB62-260C57F0783EQ39233917-C27B1122-5579-4A53-8612-0339699061AEQ40413885-929651B2-503B-4CF4-9D53-839CF9CB1641Q41126897-751A5CFA-CAA5-4299-86F9-33129609E19CQ43718495-2EFA6B79-B5E7-43A3-B9A8-057D8496D9C8Q44345567-0EBC11F8-79E1-41EB-88D5-3611B80CD068Q47142001-2734F8C3-A6D0-4930-A79D-AC752377973EQ48510022-14DB0D3F-A57B-46F9-9EBE-6E6B662B1079Q49283933-CAF86186-9CB2-49A2-9C9B-2F52EAF7CC19Q50480979-B37487A0-BE1B-48D0-93ED-97D3BCC961F7Q50964885-18316E84-BF45-4105-86E1-F8CE771327A9Q51172122-C82E1DB0-6FEA-49BA-9B7D-05BCEFA68859Q58702858-8BE27E47-D968-4611-B9EB-AC72425C07F3Q59136063-81B637A4-6835-4197-B82F-FC857500B40E
P2860
Oesophagogastric junction adenocarcinoma: which therapeutic approach?
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Oesophagogastric junction adenocarcinoma: which therapeutic approach?
@en
Oesophagogastric junction adenocarcinoma: which therapeutic approach?
@nl
type
label
Oesophagogastric junction adenocarcinoma: which therapeutic approach?
@en
Oesophagogastric junction adenocarcinoma: which therapeutic approach?
@nl
prefLabel
Oesophagogastric junction adenocarcinoma: which therapeutic approach?
@en
Oesophagogastric junction adenocarcinoma: which therapeutic approach?
@nl
P2093
P1433
P1476
Oesophagogastric junction adenocarcinoma: which therapeutic approach?
@en
P2093
Caroline Gronnier
Christophe Mariette
Guillaume Piessen
Jean Pierre Triboulet
Nicolas Briez
P304
P356
10.1016/S1470-2045(10)70125-X
P577
2010-11-23T00:00:00Z